Greenwood-based Elona Biotechnologies said it has created two subsidiaries to boost its biosimilar/biogeneric/follow-on
R&D Enterprises will develop and commercialize technology. Zimmerman Biotechnologies LLC will make protein products.
Elona develops and produces human insulin, insulin analogs, human growth hormone and other proteins to treat disease.
"We now have the ability to go all the way from the gene through a formulated drug product," said Ron Zimmerman, founder and president of Elona.
Elona last year was named by the Indiana Economic Development Corp. as one of 50 "Companies to Watch."
The new subsidiaries "will focus our efforts to meet the surge in demand for our services as world markets demand biogeneric protein products," Zimmerman added.